The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy
- 30 April 1999
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 9 (2) , 125-138
- https://doi.org/10.1006/scbi.1998.0083
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Interaction between erbB- receptors and heregulin in breast cancer tumor progression and drug resistanceSeminars in Cancer Biology, 1995
- The neu-oncogene: More than a prognostic indicator?Human Pathology, 1994
- Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancerInternational Journal of Cancer, 1991
- c-erbB-2 oncoprotein expression in primary and advanced breast cancerBritish Journal of Cancer, 1991
- Long‐term survival in breast cancer related to overexpression of the c‐erbB‐2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL‐CB11The Journal of Pathology, 1991
- correlation between histologic grade of malignancy and copy number of c-erbb-2 gene in breast carcinoma. A retrospective analysis of 176 casesCancer, 1990
- Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.Journal of Clinical Oncology, 1990
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988
- Amplification of c-erbB-2 and Aggressive Human Breast Tumors?Science, 1988
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987